306 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q4 2018 Results - Earnings Call Transcript https://seekingalpha.com/article/4241318-incyte-corporation-incy-ceo-herve-hoppenot-q4-2018-results-earnings-call-transcript?source=feed_sector_healthcare Feb 14, 2019 - Incyte Corporation (NASDAQ:INCY) Q4 2018 Results Conference Call February 14, 2019 08:00 AM ET Company Participants Mike Booth - VP, IR Hervé Hoppenot - President and CEO Barry Flannelly - EVP, Genera
Incyte (INCY) Q4 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2019/02/14/incyte-incy-q4-2018-earnings-conference-call-trans.aspx?source=iedfolrf0000001 Feb 14, 2019 - INCY earnings call for the period ending December 31, 2018.
Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/354853/incyte-incy-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-354853 Feb 14, 2019 - Incyte's (INCY) fourth-quarter earnings miss estimates but revenues beat the same on strong Jakafi sales.
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer http://www.zacks.com/stock/news/353843/mercks-keytruda-gets-fda-priority-review-for-head-neck-cancer?cid=CS-ZC-FT-353843 Feb 12, 2019 - Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Is a Disappointment in Store for Incyte (INCY) Q4 Earnings? http://www.zacks.com/stock/news/353654/is-a-disappointment-in-store-for-incyte-incy-q4-earnings?cid=CS-ZC-FT-353654 Feb 11, 2019 - Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q4 results on Feb 14.
4 Toxic Stocks to Abandon or Sell Short for Solid Gains http://www.zacks.com/stock/news/353510/4-toxic-stocks-to-abandon-or-sell-short-for-solid-gains?cid=CS-ZC-FT-353510 Feb 11, 2019 - Overpriced toxic stocks are generally susceptible to external shocks and loaded with huge amount of debt.
Incyte Down as FDA Extends Review Period of Jakafi for GVHD http://www.zacks.com/stock/news/353405/incyte-down-as-fda-extends-review-period-of-jakafi-for-gvhd?cid=CS-ZC-FT-353405 Feb 08, 2019 - The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.
4 Toxic Stocks to Get Rid Off or Sell Short for Solid Gains http://www.zacks.com/stock/news/349681/4-toxic-stocks-to-get-rid-off-or-sell-short-for-solid-gains?cid=CS-ZC-FT-349681 Jan 25, 2019 - Overhyped toxic stocks are usually susceptible to external shocks and loaded with huge amount of debt.
INCY: Gabelli & Co ups to Buy http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20190124085445 Jan 24, 2019 - Gabelli & Co issues rating change for INCY
Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs http://www.zacks.com/stock/news/348985/biotech-stock-roundup-amgen-vertex-get-ec-nod-for-label-expansion-of-drugs?cid=CS-ZC-FT-348985 Jan 23, 2019 - A low key week for the biotech sector with regular drug approvals and pipeline updates.

Pages: 1...56789101112131415...31

<<<Page 10>